Development and Production of Diagnostic Biomarkers
Pioneering a new era of precision diagnostics to elevate cancer staging and treatment.
Company Overview
GeneAssess, Inc. is dedicated to developing its breakthrough discovery of the FRY tumor suppressor gene into predictive biomarkers of epithelial cell derived tumors including those of the breast, prostate, ovary, lung and brain.
GeneAssess’s cancer program is directed at developing and commercializing novel high-value diagnostic tests that ultimately could lead to better patient outcomes through appropriate triage, earlier diagnosis, and optimal therapeutic selection.
Technology Platform
GeneAssess has developed proprietary antibodies to FRY protein and demonstrated that levels of the FRY protein expressed in human breast tumor cells, especially in the nucleus, are associated with tumor histopathology, grade cancer biomarker, hormonal status and clinical outcomes of breast cancer.
Contact Us
Want to learn more about GeneAssess or have a question about our approach? Use the contact form and let’s start a conversation.